Compare JPMorgan Equity Premium Income ETF (JEPI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Summit Therapeutics Inc — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.75 (market cap $45.55B), while Summit Therapeutics Inc trades at $17.54 (market cap $13.71B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 3.3× Summit Therapeutics Inc's market cap, and Summit Therapeutics Inc is more actively traded (6,173,057 versus 3,820,809). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 57 Days and Summit Therapeutics Inc for 16 Days on average.
| JEPI | SMMT | |
|---|---|---|
Market Cap | $45.55B | $13.71B |
Volume | 3,820,809 | 6,173,057 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $26.38 |
52-Week Low | $55.29 | $12.43 |
Typical Hold Time | 57 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.79, up 0.6% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators and key support at $56. Recent dividend activity includes three distributions averaging $0.36 per share through August-October 2026. Media coverage focuses on income generation strategies and tax implications for retirement portfolios.
The covered-call strategy provides consistent income but may limit upside during market rallies. Institutional interest remains strong with recent position increases. Key risks include interest rate sensitivity and the trade-off between yield and capital appreciation potential in rising markets.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
